PharmaFocus Today – Page 7 – media

Continuously Advancing Digital Marketing for Attenuated Live Vaccines Against Shingles

On October 28, Baike Biology (688276) held a performance briefing for the third quarter of 2024. The company’s board members, including General Manager Kong Wei, Executive Deputy General Manager Jiang Chunlai, and Board Secretary Zhang Zhe, communicated with investors regarding the operating results and financial status for the third quarter of 2024. Baike Biology is an innovative biopharmaceutical company mainly focused on infectious disease prevention and control. Since its establishment, it has primarily engaged in the research, development, production, and sale of human vaccines. The company currently has approved vaccines, including chickenpox vaccines, intranasal flu vaccines, and shingles vaccines. Among these, the chickenpox vaccine has maintained a leading market share for many years, making it one of the company’s primary sources of revenue. The intranasal flu vaccine is a part of the World Health Organization’s (WHO) Global Influenza Action Plan (GAP) and is the only attenuated live influenza vaccine administered ...
- Source: drugdu
- 47
- October 30, 2024
Endoscopic equipment company completes over 100 million yuan Series B financing

Recently, Shenzhen Xingchen Sea Medical Technology Co., Ltd. (hereinafter referred to as “Xingchen Sea Medical”) announced the completion of a Series B financing of over 100 million yuan, led by Yuansheng Venture Capital, with continued investment from old shareholders Junlian Capital and Daotong Investment, and Haoyue Capital serving as the exclusive financial advisor. It is reported that this round of financing will help Xingchen Hai Medical further expand its production capacity, accelerate new product research and development, and expand its global market, promoting its rapid development in the field of disposable endoscopes. Complete 4 rounds of financing Xingchen Sea Medical was established in October 2020, with a founding team from domestic and foreign head medical device companies. With over ten years of experience in minimally invasive surgical product research and development, global marketing, and production management, we are committed to becoming an innovative leader in endoscopic intervention diagnosis and treatment. ...
- Source: drugdu
- 57
- October 29, 2024
Significant Collaboration with Philips

On October 25, 2024, Medtronic and Philips announced the establishment of a strategic advocacy partnership centered on stroke care. The two companies will work together to raise awareness of the potential health and economic benefits that timely diagnosis and treatment of stroke can bring to patients, families, and society, and further expand and strengthen their partnership with the World Stroke Organization (WSO). It is reported that this cooperation has three key focus areas, including raising public awareness of stroke symptoms and the importance of timely medical treatment, improving treatment accessibility by increasing the number of hospitals with stroke treatment capabilities and providing training, and using advanced technology to create a comprehensive stroke care system to support early diagnosis, effective treatment, and postoperative monitoring. 01. Focus on stroke care, Philips and Medtronic reach cooperation It is reported that in this collaboration, Medtronic and Philips will work together to promote awareness of ...
- Source: drugdu
- 60
- October 29, 2024
High level introduction of anti-tumor adjuvant drugs! Sinopharm International negotiates and signs contracts with Korean and American pharmaceutical companies

The neutropenia caused by tumor chemotherapy can easily lead to potentially life-threatening complications. The Rolontis product treatment plan can effectively prevent and treat chemotherapy-induced neutropenia, helping cancer patients with treatment and recovery. Sinopharm International adheres to the functional mission of serving the national strategy and promoting people’s health and well-being. It leverages the role of Sinopharm Group’s international business strategy platform for pharmaceutical and health, introduces Rolontis products from South Korea, improves the safety and effectiveness of cancer patient treatment, and promotes the optimization and upgrading of the pharmaceutical and health supply chain industry chain.On October 24th, China Pharmaceutical Foreign Trade Co., Ltd., a subsidiary of Sinopharm International, and Hanmei Pharmaceutical Co., Ltd. signed a Rolontis product cooperation agreement, marking a new chapter of cooperation in the field of biomedicine based on pharmacy equipment cooperation between the two parties. Zhou Song, Secretary of the Party Committee and Chairman of Sinopharm ...
- Source: drugdu
- 47
- October 29, 2024
BeiGene PD-1 issues first prescription in the United States, opens new chapter with its own international solid tumor commercialization team

In late October, BeiGene’s self-developed PD-1 inhibitor, Trastuzumab (English trade name: TEVIMBRA), was launched ®， Chinese product name: Baize An ®） The first prescription was issued in the United States, officially entering the American market and bringing new treatment options to local patients. This milestone also marks the beginning of a new chapter for BeiGene’s own commercialization team for solid tumors in the United States.Teralizumab was approved by the US Food and Drug Administration (FDA) in March 2024 for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously received systemic chemotherapy (excluding PD-1/L1 inhibitors). In October 2024, BeiGene announced the commercial launch of Trastuzumab in the United States, benefiting this patient population at a price 10% lower than other PD-1 therapies approved for this indication. The first prescription of Trastuzumab in the United States has become another important milestone in the company’s ...
- Source: drugdu
- 49
- October 29, 2024
Sinocell’s “RSV vaccine 1.2 category new drug” approved for clinical trials

According to the official website of CDE, SCTV02 injection, a Class 1.2 new drug for preventive biological use developed by Sinocell Engineering Co., Ltd. (hereinafter referred to as “Sinocell”), has obtained implicit approval for clinical trials. Its indication is to prevent diseases caused by respiratory syncytial virus (RSV) infection. Respiratory syncytial virus (RSV) is an infectious virus belonging to the genus Pneumovirus of the family Paramyxoviridae. It mainly causes lower respiratory tract infections such as bronchiolitis and pneumonia in infants under 6 months old, and upper respiratory tract infections such as rhinitis and colds in older children and adults. According to statistics, almost all children have been infected with respiratory syncytial virus before the age of 2. Due to the large population base in China, the number of children with lower respiratory tract infections caused by RSV infection ranks relatively high in the world. RSV has always been called the ...
- Source: drugdu
- 60
- October 29, 2024
The first day of the national negotiations | Antiviral, anesthetic, antihypertensive drugs, etc. are being discussed! Hengrui, Hisense, Merck…appeared

On October 27, the 2024 National Medical Insurance Negotiations officially began at the National People’s Congress Conference Center in Beijing. The entrance to the venue was crowded. Some companies said that “the talks will not start until tomorrow, but we came in advance to check out the atmosphere.” This year, a total of 162 generic drugs will participate in the negotiations/bidding. The negotiations will be conducted by 25 negotiation experts from medical insurance departments selected from all over the country and divided into 5 groups. The negotiations will last until October 30, and the final results are expected to be announced in November. It is reported that the varieties of negotiations on the first day involve antiviral, anesthetic analgesic, antihypertensive and other fields. Hengrui, Merck, Kangyuan, Zhengda Tianqing, Renfu, Hisense, Xinlitai, Daiichi Sankyo, Baxter and other companies have entered the venue. Companies on the scene revealed that their Chinese medicine ...
- Source: drugdu
- 60
- October 29, 2024
Medtronic and Philips reach major cooperation

On October 25, 2024, Medtronic and Philips announced the establishment of a strategic advocacy partnership centered on stroke care. The two companies will work together to raise awareness of the potential health and economic benefits that timely diagnosis and treatment of stroke can bring to patients, families and society, and further expand and strengthen their partnership with the World Stroke Organization. It is reported that this cooperation has three key focus areas, including raising public awareness of stroke symptoms and the importance of timely medical treatment, improving treatment accessibility by increasing the number of hospitals with stroke treatment capabilities and providing training, and using advanced technology to create a comprehensive stroke care system to support early diagnosis, effective treatment and postoperative monitoring. Philips and Medtronic reach cooperation It is reported that in this cooperation, Medtronic and Philips will work together to advocate for raising awareness of the potential health and ...
- Source: drugdu
- 40
- October 29, 2024
Six major centers of the National Medical Products Administration “gathered”, and the review and approval of medical devices were fully upgraded

On October 23, with the establishment of the National Medical Products Administration Information Center in Beijing Medical Innovation Park BioPark, the six major centers of the National Medical Products Administration have been “assembled”. The six centers are the Drug Review Center of the National Medical Products Administration’s directly affiliated units, the Food and Drug Review and Inspection Center, the Drug Evaluation Center (National Drug Adverse Reaction Monitoring Center), the Medical Device Technical Review Center, the Administrative Affairs Acceptance Service and Complaint Reporting Center, and the Information Center (China Food and Drug Regulatory Data Center). Beijing Yizhuang gathers regulatory resources to provide strong guarantees for the high-quality development of biotechnology and the big health industry in terms of enterprise industry administrative approval, qualification certification, etc. In the National Bureau’s administrative affairs acceptance service hall, 10 windows are neatly arranged to handle the acceptance, consultation, charging, and certification of administrative licensing matters ...
- Source: drugdu
- 43
- October 29, 2024
Are stem cells the “terminator” of diabetes? Chinese scientists used stem cell regeneration therapy to cure type 1 diabetes for the first time

Cell, an international authoritative scientific journal, recently published a pioneering achievement from multiple research teams in China – the first time to use stem cell regeneration therapy to functionally cure type 1 diabetes. The research team used chemical reprogramming technology to induce pluripotent stem cells to prepare islet cells, and transplanted them to a type 1 diabetes patient, achieving clinical functional cure effect. So, how is it successful to induce stem cells to prepare pancreatic islet cells? Is functional cure truly a cure? Will stem cell technology be the key to conquer diabetes in the future? What is the difference between functional cure and cure Diabetes is a thorny disease, and its biggest harm to patients is that there are many clinical complications, which may lead to cardiovascular disease, nervous system damage, kidney disease, eye disease, foot disease, and so on. Diabetes ranks ninth among the world’s ten leading ...
- Source: drugdu
- 83
- October 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.